Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

ALPELISIB vs ALTEPLASE: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

ALPELISIB vs ALTEPLASE: Safety Overview

Metric ALPELISIB ALTEPLASE
Total FAERS Reports 8,419 12,687
Deaths Reported 1,271 2,540
Death Rate 15.1% 20.0%
Hospitalizations 1,705 2,083
Average Patient Age 58.8 yrs 62.5 yrs
% Female Patients 94.7% 42.4%
FDA Approval Date Apr 24, 2024 N/A
Manufacturer Novartis Pharmaceuticals Corporation Genentech, Inc.
Route ORAL INTRAVENOUS
Marketing Status Prescription Prescription